company background image
6541 logo

Tanvex BioPharma TWSE:6541 Stock Report

Last Price

NT$48.55

Market Cap

NT$8.0b

7D

-5.2%

1Y

-45.8%

Updated

27 Mar, 2024

Data

Company Financials

6541 Stock Overview

Tanvex BioPharma, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and sale of biosimilar products in Taiwan and the United States.

6541 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Tanvex BioPharma, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Tanvex BioPharma
Historical stock prices
Current Share PriceNT$48.55
52 Week HighNT$90.50
52 Week LowNT$48.10
Beta0.32
1 Month Change-24.49%
3 Month Change-25.99%
1 Year Change-45.75%
3 Year Change-81.80%
5 Year Change-77.91%
Change since IPO-87.45%

Recent News & Updates

Recent updates

Is Tanvex BioPharma (TPE:6541) Using Too Much Debt?

Mar 18
Is Tanvex BioPharma (TPE:6541) Using Too Much Debt?

Are Institutions Heavily Invested In Tanvex BioPharma, Inc.'s (TPE:6541) Shares?

Jan 19
Are Institutions Heavily Invested In Tanvex BioPharma, Inc.'s (TPE:6541) Shares?

Does Tanvex BioPharma (TPE:6541) Have A Healthy Balance Sheet?

Nov 24
Does Tanvex BioPharma (TPE:6541) Have A Healthy Balance Sheet?

Shareholder Returns

6541TW BiotechsTW Market
7D-5.2%0.3%1.9%
1Y-45.8%-21.1%26.7%

Return vs Industry: 6541 underperformed the TW Biotechs industry which returned -21.7% over the past year.

Return vs Market: 6541 underperformed the TW Market which returned 26.7% over the past year.

Price Volatility

Is 6541's price volatile compared to industry and market?
6541 volatility
6541 Average Weekly Movement4.3%
Biotechs Industry Average Movement4.3%
Market Average Movement4.2%
10% most volatile stocks in TW Market8.0%
10% least volatile stocks in TW Market1.9%

Stable Share Price: 6541's share price has been volatile over the past 3 months.

Volatility Over Time: 6541's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2013197Henry Chenhttps://www.tanvex.com

Tanvex BioPharma, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and sale of biosimilar products in Taiwan and the United States. The company focuses on delivering biosimilars which target neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis. Its products pipeline includes TX01 and TX-05 which have completed Phase III clinical trials; TX-04 and TX-16 that are in Phase I clinical trial; and TX-52 and other products which are in pre-clinical trial.

Tanvex BioPharma, Inc. Fundamentals Summary

How do Tanvex BioPharma's earnings and revenue compare to its market cap?
6541 fundamental statistics
Market capNT$7.96b
Earnings (TTM)-NT$2.14b
Revenue (TTM)NT$61.41m

129.6x

P/S Ratio

-3.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
6541 income statement (TTM)
RevenueNT$61.41m
Cost of RevenueNT$1.71m
Gross ProfitNT$59.70m
Other ExpensesNT$2.20b
Earnings-NT$2.14b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-13.03
Gross Margin97.22%
Net Profit Margin-3,480.00%
Debt/Equity Ratio0%

How did 6541 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.